Blueprint Medicines, a Sanofi company, today announced AYVAKIT® (avapritinib) data showing clinically meaningful outcomes and a well-tolerated long-term safety profile in patients with indolent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results